Dr. Steve Bui, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 444
Licensed in California since 2002, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
CA license A77823 (first issued 2002; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Providence St. Joseph Hospital Orange, CA
- Orange County Global Medical Center Santa Ana, CA
- Coastal Communities Hospital Santa Ana, CA
Medical groups
- Southern California Kidney Consultants Inc (21 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 444
- Services billed
- 2,303
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 818 | 157 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 381 | 55 |
| Established patient office or other outpatient visit, 30-39 minutes | 345 | 174 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 174 | 51 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 81 | 44 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amlodipine Besylate Other prescribers in Garden Grove, CA | 199 |
| Lisinopril Other prescribers in Garden Grove, CA | 143 |
| Furosemide Other prescribers in Garden Grove, CA | 100 |
| Losartan Potassium Other prescribers in Garden Grove, CA | 95 |
| Atenolol Other prescribers in Garden Grove, CA | 80 |
| Metoprolol Succinate Other prescribers in Garden Grove, CA | 78 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Garden Grove, CA | 78 |
| Sevelamer Carbonate Other prescribers in Garden Grove, CA | 68 |
| Prosol (parenteral amino acid 20% no.1) | 55 |
| Hydralazine Hcl Other prescribers in Garden Grove, CA | 49 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $185 in total to this clinician.
| Akebia Therapeutics Inc | $145 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $23.01 |
| AstraZeneca Pharmaceuticals LP | $16.75 |
| Food and Beverage | $185 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $346,646 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.